RxDoctor Payments Data

Chara Solich, MD

Rheumatology · Meridian, IDNPI 1134158892

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,831 of the $2,191 with a category attached, or 83.6%. 15 manufacturers reported payments, led by Amgen at 39.5% of the total. Reporting peaked in 2023 at $819 and has fallen 67.2% since, to $269 in 2025.

$2,191in general payments, 2019–2025

Across 153 payments — averaging $14.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$865
  • UCB, Inc.$484
  • Johnson & Johnson$365
  • Regeneron Healthcare Solutions, Inc.$123
  • Pfizer$64
  • Genentech USA, Inc.$55
  • plus $236 from 9 others

What the payments were for

  • Food & beverage$1,83184%
  • Education$36016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,191 in reported general payments places this provider in the 60th percentile of 28 rheumatology providers in Idaho.

See all rheumatology providers in Idaho

Medicare billing

Part B allowed, 2024
$304,857
Medicare patients
137
Services billed
11,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate32$249,347
Enbrel SureclickEtanercept25$184,320
Humira(Cf)Adalimumab11$152,856
Cosentyx Sensoready PenSecukinumab13$93,629
OrenciaAbatacept12$68,319
ActemraTocilizumab14$51,676
Hydroxychloroquine Sulfate274$8,360
Leflunomide106$6,936
MethotrexateMethotrexate Sodium344$6,011
Sulfasalazine59$2,115
Sulfasalazine DrSulfasalazine26$1,803
Diclofenac Sodium17$1,301
Colchicine15$1,058
Azathioprine18$954
Prednisone140$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$46$152,85611 claims
E.r. Squibb & Sons, L.L.C.Orencia$41$68,31912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 rheumatology providers in Idaho.

Other rheumatology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →